BiotechTube

MEDI7352

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Painful Diabetic Neuropathy

Conditions

Painful Diabetic Neuropathy

Trial Timeline

Nov 19, 2018 → Jun 29, 2023

NCT ID
NCT03755934

About MEDI7352

MEDI7352 is a phase 2 stage product being developed by AstraZeneca for Painful Diabetic Neuropathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03755934. Target conditions include Painful Diabetic Neuropathy.

What happened to similar drugs?

7 of 20 similar drugs in Painful Diabetic Neuropathy were approved

Approved (7) Terminated (2) Active (11)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄QUTENZAAstellas PharmaPhase 3
✅Qutenza + PregabalinAstellas PharmaApproved
✅duloxetine hydrochlorideEli LillyApproved
🔄Duloxetine hydrochloride + placeboEli LillyPhase 3
🔄Duloxetine + PlaceboEli LillyPhase 3
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04675034Phase 2Completed
NCT03755934Phase 2Terminated

Competing Products

20 competing products in Painful Diabetic Neuropathy

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
duloxetine hydrochlorideEli LillyApproved
43
Duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
43
Duloxetine + Pregabalin + PlaceboEli LillyPhase 3
40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
35
GRC 17356 + Matching PlaceboGlenmark PharmaceuticalsPhase 2
35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + PlaceboGlenmark PharmaceuticalsPhase 2
27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)Johnson & JohnsonPhase 3
32
AZD5213 + pregabalin + Placebo + pregabalin capsulesAstraZenecaPhase 2
35
MEDI7352AstraZenecaPhase 2
35
MEDI7352 + PlaceboAstraZenecaPhase 1
29
MK-6096 + PlaceboMerckPhase 2
35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochlorideMerckPhase 2
27
EMA401 + PlaceboNovartisPhase 2
27
PregabalinPfizerPhase 3
40